Big deals in Big Pharma
The battle between Novo Nordisk and Pfizer to acquire Metsera is over. But is this merger a sign of strength or weakness for the industry? Today on the show, Rob Armstrong talks with US finance editor James Fontanella-Khan about the pressures on drug companies from Washington and the market. Also they go long Nasdaq…
We score an episode from what we can actually measure — its reach and engagement, what listeners say about it, and what it covers. We don't have those signals for this one yet, so it doesn't get a number.
Buzzmeter says it's buzzing across platforms — the Hive Vote says whether the people who actually listened liked it.
Rate this episode
Add your vote to the Hive — listeners rate every episode after they finish.
- No reviews yet — be the first.
Similar episodes from other shows
More like Unhedged →
Pfizer and Novo Nordisk’s $10bn battle over weight-loss drugs
Pfizer plays hardball in weight-loss drug fight
Big Pharma Has a Case of Merger Mania
What’s News in Earnings: Who Is Winning the Obesity-Drug Arms Race?
One great episode in your inbox, daily — free.
One email a day, unsubscribe anytime. No spam, ever.